Cadenza Bio, an Oklahoma City, OK-based biotechnology company, raised $2.44M in Series Seed funding.
The round was led by Plains Ventures, with participation from the Oklahoma Life Science Fund, Cortado Ventures, Boyd Street Ventures, and Illinois Ventures.
The company intends to use the funds to focus on therapeutic drug development to promote remyelination in Multiple Sclerosis.
Led by CEO Carol Curtis, Cadenza Bio accelerates and supports the development of a series of novel, and highly selective Estrogen Receptor β (ERβ) targeting small-molecule compounds. It is dedicated to advancing therapeutic drugs that will make a meaningful impact in the lives of patients suffering from debilitating diseases.
Launched in 2022 through a partnership between SmartHealth Catalyzer in Chicago and Ascend BioVentures in Oklahoma City, Cadenza Bio holds an exclusive license to technology developed through an academic research collaboration between Dr. John Katzenellenbogen of the University of Illinois Urbana-Champaign (UIUC) and Dr. Seema Tiwari-Woodruff of the University of California, Riverside (UCR) and funded, in part, by the National Multiple Sclerosis Society’s Fast Forward commercial research program.
FinSMEs
14/12/2023